Trials / Active Not Recruiting
Active Not RecruitingNCT06706427
Safety and Efficacy Study of NGGT001 in Bietti Crystalline Corneoretinal Dystrophy Subjects
A Phase I/II Study for Subretinal Injection of NGGT001 in Patients With Bietti Crystalline Corneoretinal Dystrophy
- Status
- Active Not Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 12 (actual)
- Sponsor
- NGGT (Suzhou) Biotechnology Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to evaluate the safety, tolerability, and efficacy of subretinal injection of NGGT001 in patients with Bietti Crystalline Corneoretinal Dystrophy (BCD) and to recommend the optimal dosage for future clinical administration.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | NGGT001 | Using a recombinant adeno-associated virus (AAV) vector to deliver the gene CYP4V2 via subretinal injection for the treatment of crystalline retinal degeneration. |
Timeline
- Start date
- 2024-03-21
- Primary completion
- 2025-11-30
- Completion
- 2029-09-26
- First posted
- 2024-11-26
- Last updated
- 2025-05-25
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT06706427. Inclusion in this directory is not an endorsement.